Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Delayed Nasdaq Stockholm 07:59:43 2023-11-03 EDT			5-day change	1st Jan Change
0.1604 ^SEK	-1.11%		-.--%	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Market Cap	182M 19.19M 16.44M 15.38M 14.08M 26.43M 1.84B 26.78M 70.88M 922M 72.07M 70.5M 3.05B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 41.77M 35.78M 33.48M 30.65M 57.51M 4B 58.27M 154M 2.01B 157M 153M 6.64B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

25-06-27	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-06-17	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
23-11-03	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
23-10-24	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23-10-23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
23-10-20	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
23-10-20	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
23-10-19	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
23-10-16	Irras Obtains Extension for SEK20 Million Loan	MT
23-10-15	Irras extends SEK 20 million short-term loan	FW
23-10-02	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
23-09-18	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
23-06-30	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
23-05-22	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
23-05-21	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
23-02-20	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

IRRS ABNPV Stock

Stocks

IRRAS

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRS ABNPV

Latest news : IRRS ABNPV

Analysts' recommendations: IRRS ABNPV

Press Releases: IRRS ABNPV

Quotes and Performance

Course Extremes

Managers and Directors: IRRS ABNPV

Medical Devices & Implants

Financials

Company Profile

23-10-20	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
23-10-19	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
23-10-19	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
23-10-16	IRRAS publishes prospectus	AQ
23-10-15	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	2021-06-30
Griffen Stapp DFI	Director of Finance/CFO	40	2021-06-16
Sten Gustafsson IRC	Investor Relations Contact	-	2021-03-08

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	2015-05-31
Marios Fotiadis CHM	Chairman	53	2020-08-17
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	2017-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRS ABNPV	-1.11%	-.--%	-.--%	-10.89%	16.9M
STRYKER CORPORATION	+0.53%	-2.88%	-16.43%	+19.59%	126B
SMITH & NEPHEW PLC	-0.37%	-2.42%	-22.67%	+0.75%	12.26B
GLAUKOS CORPORATION	0.00%	+0.20%	+96.38%	+148.34%	10.9B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-4.90%	-8.39%	-52.04%	-69.44%	4.14B
DOUBLE MEDICAL TECHNOLOGY INC.	-0.43%	-1.43%	-24.31%	+48.56%	2.69B
INSPIRE MEDICAL SYSTEMS, INC.	+1.78%	+9.21%	-35.03%	-71.13%	1.8B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-1.13%	-0.43%	-23.65%	-12.13%	1.66B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-3.68%	-3.53%	-35.52%	-37.74%	1.61B
Average	-1.03%	-0.62%	-12.59%	+1.77%	17.94B
Weighted average by Cap.	+0.23%	-2.52%	-10.80%	+23.14%

	2023	2024
Net sales	42.88M 4.53M 3.88M 3.63M 3.32M 6.23M 433M 6.32M 16.72M 218M 17M 16.63M 720M	57.98M 6.12M 5.25M 4.91M 4.49M 8.43M 586M 8.54M 22.61M 294M 22.99M 22.49M 973M
Net income	-209M -22.06M -18.89M -17.68M -16.18M -30.37M -2.11B -30.77M -81.46M -1.06B -82.83M -81.02M -3.51B	-95.98M -10.14M -8.68M -8.12M -7.44M -13.96M -970M -14.14M -37.43M -487M -38.06M -37.23M -1.61B
Net Debt	43.85M 4.63M 3.97M 3.71M 3.4M 6.38M 443M 6.46M 17.1M 223M 17.39M 17.01M 736M	214M 22.58M 19.34M 18.1M 16.56M 31.09M 2.16B 31.5M 83.37M 1.09B 84.77M 82.93M 3.59B

3 years	0.16	0.19
5 years	0.11	5.2
10 years	0.11	47